# Association of vitamin D level and maternal gut microbiome during pregnancy: Findings from a randomized controlled trial of antenatal vitamin D supplementation

Andrea Aparicio, PhD<sup>1</sup>, Diane R. Gold, MD, MPH<sup>1,2</sup>, Scott T. Weiss, MD, MS<sup>1</sup>, Augusto A. Litonjua, MD, MPH<sup>3</sup>, Kathleen Lee-Sarwar, MD, MS<sup>1,4\*</sup>, Yang-Yu Liu, PhD<sup>1,5\*</sup>

 <sup>1</sup> Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
 <sup>2</sup> Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, MA, USA
 <sup>3</sup> Division of Pediatric Pulmonary Medicine, Golisano Children's Hospital at Strong, University of Rochester Medical Center, Rochester, NY, USA
 <sup>4</sup> Division of Allergy and Clinical Immunology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
 <sup>5</sup> Center for Artificial Intelligence and Modeling, The Carl R. Woese Institute for Genomic Biology, University of Illinois at Urbana-Champaign, Champaign, IL, USA

> \*Corresponding authors. Email: klee-sarwar@bwh.harvard.edu, yyl@channing.harvard.edu Address: 181 Longwood Ave, Boston, MA 02115 Telephone: 617-525-2714

Sources of support: VDAART was funded by U01HL091528 from the National Heart, Lung, and Blood Institute. Additional funding came from NIH grants K08HL148178, R01HL108818, T32HL742742, and ECHO grant OD023268. Y.-Y.L. acknowledges the funding support from National Institutes of Health (R01AI141529, R01HD093761, RF1AG067744, UH3OD023268, U19AI095219, and U01HL089856).

Conflicts of interest: Andrea Aparicio: no conflicts of interest; Diane R. Gold: no conflicts of interest; Scott T. Weiss: no conflicts of interest; Augusto A. Litonjua: no conflicts of interest; Kathleen Lee-Sarwar: no conflicts of interest; Yang-Yu Liu: no conflicts of interest.

## 1 Abstract

2 Shifts in the maternal gut microbiome and vitamin D deficiency during pregnancy have been 3 associated, separately, with health problems for both the mother and the child. Yet, they have 4 rarely been studied simultaneously. Here, we analyzed gut microbiome (from stool samples 5 obtained in late pregnancy) and vitamin D level (from blood samples obtained both in early 6 and late pregnancy) data of pregnant women in the Vitamin D Antenatal Asthma Reduction 7 Trial (VDAART), a randomized controlled trial of vitamin D supplementation during 8 pregnancy, to investigate the association of vitamin D status on the pregnant women's 9 microbiome. To find associations we ran linear regressions on alpha diversity measures, 10 PERMANOVA tests on beta diversity distances, and used the ANCOM-BS and Maaslin2 11 algorithms to find differentially abundant taxa. Analyses were deemed significant using a cut-12 off p-value of 0.05. We found that gut microbiome composition is associated with the vitamin 13 D level in early pregnancy (baseline), the maternal gut microbiome does not show a shift in 14 response to vitamin D supplementation during pregnancy, and that the genus *Desulfovibrio* is 15 enriched in women without a substantial increase in vitamin D level between the first and the 16 third trimesters of pregnancy. We conclude that increasing the vitamin D level during 17 pregnancy could be protective against the growth of sulfate-reducing bacteria such as 18 Desulfovibrio, which has been associated with chronic intestinal inflammatory disorders. More 19 in-depth investigations are needed to confirm this hypothesis.

## 21 Introduction

22	Vitamin D has been strongly associated with many conditions of human health. Initially it was
23	discovered to promote bone health [1,2] but now it is known to have many other
24	physiological functions among which, importantly, are modulating immunological and
25	inflammation responses [3–5]. Vitamin D can be obtained from supplements, diet or sun
26	exposure and is converted by the liver into its serum form 25-hydroxyvitamin D which, in
27	turn, is converted into its activated form 1,25-dihydroxyvitamin D [6] by the kidneys and
28	many other cells in the body. The biological activity of vitamin D's active form in the body is
29	mediated by the vitamin D receptor (VDR), primarily expressed in the intestines, kidneys,
30	parathyroid gland and bones, though also expressed by several cells of the immune
31	system [7]. In the gut, a growing amount of evidence indicate that vitamin D and VDR
32	signaling are responsible for maintaining epithelial integrity and modulating immune and
33	inflammatory responses when the barrier is penetrated by bacteria, leading to chronic states of
34	inflammation when the signaling is disrupted [6,8].
35	
36	The gut microbiome is composed of trillions of microbes that collectively influence the health
37	of its host [9]. In particular, the gut microbiome is known to have important
38	immunoregulation functions [10] and disruptions of it are associated with chronic
39	inflammatory diseases [11,12]. Strong evidence that vitamin D is associated with microbiota
40	alterations exists, but the results are considerably heterogeneous [13–15].
41	
42	The gut microbiome composition changes with age and is naturally modified during several

43 stages of life. During pregnancy, the microbiome shift often resembles diseased states or

44 dysbiosis that, surprisingly, instead of leading to a decline in fitness, promotes

45 homeostasis [16]. The gut microbiome is dramatically modified between the first and third

46 trimesters of pregnancy and bacteria related to inflammation and immune response processes

47 are usually elevated as the pregnancy progresses [17,18].

48

49 The impact on the offspring of maternal vitamin D level in serum and of vitamin D 50 consumption during pregnancy has been studied several times, establishing associations with 51 the children's microbiome and with outcomes such as changes in the immune system 52 modulation, asthma/allergic disease incidence, likelihood of C. difficile colonization, and 53 changes in microbiome richness and composition [19–21]. However, to our knowledge, no 54 clinical trials have focused on the impact of vitamin D consumption on the mothers' own 55 microbiome during pregnancy. One observational study found an association between vitamin 56 D dietary intake and a reduction of microbiome richness, and an increase of bacteria with pro-57 inflammatory properties [22], however, due to the lack of serum vitamin D level 58 measurements, and considering that its absorption may depend on many factors other than 59 only diet, the knowledge gap persists. Changes in the maternal gut microbiome are known to be associated with the development of preeclampsia, gestational diabetes and other serious 60 61 pregnancy pathologies [23] and with negative offspring outcomes, especially with those 62 related to immunity or allergic diseases [24–26]. Thus, exploring the effects of maternal 63 vitamin D status on their microbiome is not only useful to identify potential associated 64 pregnancy complications or impacts on the mothers' health. Additionally, it has been 65 repeatedly shown that the maternal and infant microbiome are related [24,25,27,28] and,

therefore, this direction of research can also contribute to discover potential consequences forthe children's health .

68

69	Here we analyze the 16S rRNA data generated from stool samples of 114 pregnant women in
70	the Vitamin D Antenatal Asthma Reduction Trial (VDAART), a multi-site randomized,
71	double-blind, placebo-controlled trial of vitamin D supplementation during pregnancy, to look
72	for associations between the participants' vitamin D status and their gut microbiome during
73	the third trimester of pregnancy. We use three different measures for vitamin D status: (1)
74	baseline vitamin D level; (2) treatment assignment; and (3) change in vitamin D level over the
75	trial period. In the following, we present three key findings. First, the baseline vitamin D level
76	is associated with the gut microbiome composition. Second, the gut microbiome is robust
77	enough such that the vitamin D supplementation (even with up to 4,400 IU cholecalciferol
78	daily) during pregnancy does not significantly modify it. Third, Desulfovibrio, a genus of
79	Gram-negative sulfate-reducing bacteria, is enriched in women whose vitamin D level did not
80	have a substantial increase (less than10ng/mL) over the trial period.
81	

### 82 Methods

### 83 Vitamin D Antenatal Asthma Reduction Trial (VDAART)

84 VDAART is a randomized controlled trial of Vitamin D supplementation during pregnancy to

85 prevent asthma in offspring conducted in the United States (St. Louis, Boston, and San Diego;

- 86 NCT00920621). 870 women were enrolled at 10-18 weeks of gestation and randomized to
- 87 receive either a high dose of vitamin D oral supplements (4,400 IU cholecalciferol daily,
- 88 called *treatment or high dose treatment* hereafter) or a *placebo* dose of vitamin D oral

supplements (400 IU cholecalciferol daily) between enrollment and delivery. The study
protocol was approved by the institutional review boards at each participating institution and
at Brigham and Women's Hospital. All participants provided written informed consent [29].

#### 93 Stool sample collection and processing

94 During the third trimester of pregnancy (weeks 32-38 gestation), 120 participants of the 95 VDAART trial provided a stool sample. Subjects were asked to collect a 0.5 teaspoon-sized 96 sample 1 to 2 days before a study visit and store the sample in a home freezer before transport 97 with a freezer pack to the study site. Stool was not collected if participants had used antibiotics 98 in the past 7 days. After delivery to the study site, stool samples were immediately stored at -99 80°C. Microbiome profiling was performed by sequencing the 16S rRNA hypervariable region 100 4 (V4 515F/816R region) on the Illumina MiSeq platform at Partners Personalized Medicine 101 (Boston, MA). Of the 120 stool samples collected, 2 with fewer than 1,000 reads measured 102 were excluded from the analysis, leaving 118 samples. 103

### 104 Blood sample collection and processing

105 Maternal blood samples were collected at two time points: at enrollment at 10-18 weeks of

106 gestation and at 32-38 weeks of gestation. The serum 25-hydroxyvitamin D 25(OH)D level

107 (termed as vitamin D level hereafter) was measured in both samples using the DiaSorin

108 LIAISON method (a chemiluminescence assay) at the Channing Division of Network

109 Medicine, Brigham and Women's Hospital (Boston, MA). All the 118 women who provided a

110 stool sample in the third trimester of pregnancy had provided a blood sample at the first time

111 point (yielding a baseline vitamin D level) and 114 of them also provided one at the second

112 time point (yielding a *final* vitamin D level). Therefore, we have blood samples to analyze the

- 113 change in vitamin D level between early and late pregnancy of 114 women; 59 of them were
- 114 on the treatment group and the remaining 55 were on the placebo group.
- 115

#### 116 Serum vitamin D level

117 For the 114 women with baseline and final measurements (Figure 1.a-b), we calculated the 118 vitamin D level *difference* as the final level value minus the baseline level value; the mean 119 vitamin D level difference among the 114 women was of 11.2 ng/mL (Figure 1.c). We used a 120 rounded cut-off of 10 ng/mL to categorize the women into two groups: high change (difference 121 of more than 10 ng/mL in serum 25hydroxyvitamin D 25(OH)D) and low change (difference 122 equal to or less than 10 ng/mL in serum 25-hydroxyvitamin D); 62 women fell into the high 123 change group and 52 in the low change group. Additionally, we created a variable that 124 simultaneously accounts for the change of vitamin D level and the baseline vitamin D level (see 125 SI for details and corresponding analysis).

126

#### 127 Mothers' characteristics

The stool and blood samples were collected at three different sites: Boston, MA; San Diego, CA, and St. Louis, MI. The available subjects' characteristics from the initial enrollment questionnaire are the mothers' age, race, education, household income, and history of asthma and hay fever. Mothers were categorized into groups for each factor except for their age which was kept as a continuous variable. Race and ethnicity information was collected because they are determinants of circulating 25-hydroxyvitamin D levels; the race and ethnicity of every participant was self-reported. Participants were asked to first categorize themselves as either

105	TT' '	TT'	• .1		· .1 ·	• .	· · · 1	· ·
1 4 5	Highonic	or non Hier	nonic than	to cotoror	170 thoir roc	a into nra	nacitiad	cotocorioc
1.).)	THSDAILIC	OI HOH-I HSI	инс. шст		עמד נווכח במט		NUCLINCU	CALEPULIES.
		1		0			1	U

- 136 Race/ethnicity (called *race* hereafter) groups were collapsed into 3 groups for the analysis:
- 137 Black or African American mothers (called *Black mothers* hereafter), White, non-Hispanic
- 138 mothers (called *White mothers* hereafter), and Hispanic mothers and mothers of other race
- 139 (n=25 and n=9, respectively, called *Other race* hereafter). Education groups: higher education
- 140 (some college education or more, n=94) and lower education (technical school, high-school, or
- 141 less, n=20). Income groups: higher income (household income of more than 50 000 U.S.
- 142 dollars/year, n=35) and lower income (less than 50 000 U.S. dollars/year, n=50). History of
- 143 asthma or hay fever: yes (n=39, n=65, resp.) or no (n=65, n=49, resp).
- 144

### 145 Statistical Analyses

146 For the statistical analyses we measured vitamin D status in three different ways: baseline

147 vitamin D level (measured at enrollment), randomized treatment assignment (treatment or

148 placebo supplementation), and vitamin D level *change* between baseline and final

149 measurements (high or low change). Unless specifically noted, we used a cut-off p-value of

150 0.05 to deem results statistically significant for all our analyses. All analyses of microbiome

associations were adjusted for two *a priori* selected potential covariates: participants' race and

- 152 education level, unless otherwise specified.
- 153

### 154 Alpha Diversity

155 Alpha diversity measures are estimates of an individual sample's taxonomic diversity. We

156 computed the observed richness, Shannon, and Simpson indices using the *Phyloseq* package in

157 R [30]. The observed richness simply counts the number of different taxa present in each

sample. The Shannon and Simpson indices incorporate the measures of richness and evenness

159 of every sample. We used Wilcoxon rank-sum tests and covariate adjusted linear regressions

160 to compare the samples' estimates of these three alpha diversity metrics by measures of

161 vitamin D status.

162

### 163 Beta Diversity

164 Beta diversity measures quantify the dissimilarity in taxonomic composition between two

samples. We computed the following measures: Bray-Curtis dissimilarity, Jaccard distance,

166 Unifrac distance, and Weighted-Unifrac distance using the *Phyloseq* package in R. We used

167 the adonis2 algorithm in the R package *vegan* [31], which performs PERMANOVA tests

168 using the distance matrices, to find associations between the beta-diversity dissimilarity

169 measurements and measures of maternal vitamin D status.

170

#### 171 Abundance Association Analysis

172 To ensure robustness of the identified associations, we used two different methods, and their 173 corresponding R packages, that look for associations between the subjects variables and the 174 abundance of specific taxa: ANCOM-BC [32] and MaAsLin [33]. ANCOM-BC is a 175 differential abundance method that uses a log-linear regression framework with a sample-176 specific offset term to account for differences in sampling fraction between samples. MaAsLin 177 is a multivariate association method that uses additive linear models to detect associations 178 between specific groups and the abundance of taxa simultaneously treating all the present taxa 179 as outcomes. We used the *false discovery rate* (FDR) method to adjust the p-values for 180 multiple comparisons. The association analyses were performed on genus-level data.

181

### 182 **Results**

#### 183 Subject characteristics

184 The mean baseline vitamin D level in early pregnancy among all 114 participants was 21.08 185 ng/mL (Figure 1.a). Table 1 summarizes the participants' characteristics with respect to their 186 baseline vitamin D level. We found a significant association between the baseline vitamin D level and the mothers' race, income, and education level (ANOVA p-value =  $3.6 \times 10^{-9}$ , 187  $2.8 \times 10^{-4}$ , 0.01, respectively). Black women tended to have the lowest baseline vitamin D 188 189 level, White women tended to have the highest, and Latino/Hispanics and other women of other races tended to be in between; women with lower income and women with lower education 190 191 tended to have lower levels of baseline vitamin D (Figure 1.d). The race and education variables 192 were included as covariates in all downstream analyses, while the household income was 193 excluded from the covariates due to high missingness (29 women, i.e., 25% of our cohort did 194 not provide income data) and because it is strongly correlated with maternal education and race (Chi-squared test p-value  $< 7 \times 10^{-3}$ ,  $5 \times 10^{-4}$ , respectively). Additionally, we found a 195 196 significant association between the collection site and the women's baseline vitamin D level 197 (ANOVA p-value < 0.001). The collection site is correlated with the subjects' race (Chi-squared 198 test p-value < 0.0005) and thus it was also excluded from the covariates. The baseline vitamin 199 D level was treated as a continuous variable in all the downstream analyses except for the 200 differential abundance algorithm ANCOM-BC, for which we used the mean baseline vitamin D 201 level of 21.01 ng/mL as a cut-off to define two groups: below the mean and above the mean.

203 The participants of VDAART were randomized to receive either a high (4400 IU daily 204 cholecalciferol) or a low (400 IU daily cholecalciferol) dose of vitamin D supplements (called 205 *treatment* or *placebo*, respectively, hereafter) [34,35]. Table 2 summarizes the participants' 206 characteristics stratified by their treatment assignment, revealing that the randomization 207 performed for the original VDAART cohort (>800 women) resulted in similar baseline 208 characteristics between treatment groups among the 114 women with baseline and final 209

210

vitamin D measurements.

211 Most of the 114 women had an increased vitamin D level between early and late pregnancy, 212 though the extent of vitamin D increase varied between participants (Figure 1.a). The mean 213 difference between the baseline and final vitamin D level among the participants was 11.2 214 ng/mL. A cut-off of 10 ng/mL in vitamin D level difference yielded two groups: high vitamin 215 D level change (increase of at least 10 ng/mL) with 62 subjects, and low vitamin D level change 216 (decrease in vitamin D or increase of less than 10ng/mL) with 52 subjects. We did not find any 217 significant associations between the change groups and the participants' characteristics, 218 suggesting that the vitamin D level change was likely not confounded by them (Table S2). The 219 vitamin D level in women in the treatment group (n=59) increased by 16.8 ng/mL on average 220 (48 of them fell in the high change group and 11 of them in the low change group), while the 221 vitamin D level in the women in the placebo group (n=55) increased by only 5.11 ng/mL on 222 average (14 of them fell into the high change group and 41 of them in the low change group). 223 The treatment assignment is significantly associated with the vitamin D level change assignment (Chi squared test p-value  $< 6.7 \times 10^{-9}$ , Figure S3.b). A significant vitamin D level difference 224 225 between the treatment groups, and the absence of an association with the baseline vitamin D

level were also reported for the entire VDAART cohort [34]. We found that the vitamin D level change was not associated with the baseline vitamin D level (Figure S3.a). To further reduce the risk of confounding, we ran all the downstream analysis for a variable baseline-change combination variable, with no qualitative changes to the results (SI).

230

### 231 Microbiome composition is associated with baseline vitamin D level

232 We found a small but not statistically significant positive correlation between the baseline

233 vitamin D level and gut microbiome richness or for the three alpha diversity indices analyzed

234 (Figure 2.a). We found a significant association between the women's baseline vitamin D

235 level and their microbiome composition for all beta diversity measurements (Bray-Curtis,

Jaccard, Unifrac and W-Unifrac adonis2 (PERMANOVA) p-values < 0.025, 0.025, 0.015, and

237 0.045, respectively). This association was not modified in models adjusted for education and

238 race (Bray-Curtis, Jaccard, Unifrac and W-Unifrac adjusted adonis2 (PERMANOVA) p-

values < 0.015, 0.015, 0.015, and 0.035, respectively). A covariate adjusted (education and

race) linear regression between every pair of subjects' difference in baseline vitamin D and the

241 corresponding beta diversity distance between them confirmed the significant association (p-

242 value  $< 2 \times 10^{-16}$  for all distances, Figure 2.b). However, specific individual taxa associated

243 with baseline vitamin D were not identified by either the ANCOM-BC or MaAsLin2

algorithms adjusted for both education and race (all FDR > 0.05 at the genus level).

245

### 246 Gut microbiome is robust to vitamin D supplementation during pregnancy

247 In an intention-to-treat analysis, we found no significant associations between the participants'

treatment assignment and any of the alpha diversity indices that we calculated (Figure 2.c),

249	suggesting that the vitamin D supplementation did not modify the participants' microbiome
250	diversity during the trial period. We also did not find any significant associations with the
251	analyzed beta diversity measurements. (Figure 2.d), suggesting that the microbiome
252	composition was not altered with the short-term treatment during pregnancy. Additionally,
253	both differential abundance algorithms, ANCOM-BC and MaAsLin2, failed to identify any
254	taxa that was significantly differentially expressed between the groups (all FDR $> 0.05$ ). This
255	suggests that the microbiome during pregnancy is robust to short-term vitamin D
256	supplementation over the treatment period.

257

### 258 Change in vitamin D level does not impact microbiome diversity

259 Comparing participants by the change in their vitamin D level allows for assessment of the 260 impact of vitamin D over a relatively short period (between week 10-18 and week 32-38 of 261 pregnancy) on the microbiome, and accounts for potential lack of adherence to the vitamin D 262 supplementation treatment assignment. All the vitamin D level change analyses were adjusted 263 for the participants' baseline vitamin D level in addition to their race and education. We found 264 no significant associations between the participants' vitamin D change and their microbiome 265 richness for any of the alpha diversity indices that we analyzed. We also found no significant 266 associations with the women's microbiome composition for any of the analyzed beta diversity 267 measurements. This suggests that the microbiome richness and composition are robust to 268 changes in the vitamin D level during pregnancy.

269

## 270 Desulfovibrio is enriched in pregnant women with low change of vitamin D

271 level

272	Next, we looked at differentially abundant taxa between the change groups at the genus level.
273	We found that two genera were enriched in the low change group (Clostridium sensu stricto 1
274	and <i>Desulfovibrio</i> , ANCOM-BC p-value < 0.04 and 0, respectively), and that two genera were
275	depleted ( <i>Coprococcus</i> and <i>Fusicatenibacter</i> , ANCOM-BC p-value < 0.02 for both) (Figure 3.a).
276	However, after adjusting for multiple comparisons, only Desulfovibrio remained significantly
277	differentially abundant (ANCOM-BC FDR < 0.01, log fold change = 0.0064). MaAsLin analysis
278	also revealed an enrichment in Desulfovibrio in women with low change in vitamin D
279	(coefficient of 0.04 and p-value $< 8 \times 10^{-5}$ , q-val $< 0.01$ , blue line in Figure 3.b). Indeed,
280	Desulfovibrio was expressed almost exclusively in participants that had a low change of vitamin
281	D level (area on the left of solid gray line in Figure 3.b), and it was not expressed in any of the
282	participants whose vitamin D level increased by 15 ng/mL or more (area on the right of the
283	discontinuous line in Figure 3.b). Finally, we found significant associations between the relative
284	abundance of Desulfovibrio and (Figure 3.c) the participants' history of asthma (linear model
285	adjusted for education level coefficient of 0.0045 and p-value < 0.016), education, and income,
286	(Wilcoxon rank sum test p-val $< 0.03$ , for both). We found a weak association between the
287	abundance of <i>Desulfovibrio</i> and the participants' race (ANOVA p-value=0.671) and no
288	significant association with treatment assignment. In particular, Desulfovibrio was not present in
289	stool samples from any White participant and was less abundant in participants with higher
290	income and education compared to those with lower income and education. However, the

291	significant associations between the abundance of <i>Desulfovibrio</i> and vitamin D change were
292	preserved after adjusting the ANCOM-BC and MaAsLin algorithms for race and education as
293	covariates. Noteworthy, a linear model adjusted for education level showed that there is no
294	significant association between Desulfovibrio and the mothers' baseline vitamin D level, but
295	analyses simultaneously accounting for the change of vitamin D level and the baseline vitamin D
296	level pointed toward an enrichment of Desulfovibrio among participants with a low increase in
297	vitamin D over pregnancy (see SI for detailed results).

298

299	Interestingly, we found that the presence of <i>Desulfovibrio</i> is negatively, yet weakly, correlated
300	with a low consumption of fruits, when adjusted for education level (maternal diet summary
301	derived from the principal component analysis of an 18-item food frequency questionnaire data.
302	The second principal component represents a diet low in citrus and other fruits. Adjusted linear
303	regression p-value = 0.0826). Additionally, we found that <i>Desulfovibrio</i> was present in a very
304	small proportion (1.6%, n=4) of the offspring gut microbiomes in 244 children who provided a
305	stool sample between 3 and 6 months of age. None of the infants with a presence of
306	Desulfovibrio were born to White mothers, mothers with higher income or had developed asthma
307	at 3 or 6 years old.

308

## 309 **Discussion**

310 Here we described the vitamin D status in pregnant women in three different ways (baseline311 vitamin D level, randomization to high or low dose vitamin D supplementation, and vitamin D

level change over the trial period), each one shedding light on the relationship with the gutmicrobiome in its own way.

314

315 The baseline vitamin D level (measured at enrollment at 10-18 weeks of gestation) provides a 316 perspective of the mothers' background in terms of their vitamin D status. For example, it 317 might reflect their eating habits, history of supplementation, exposure to the sun, and/or ability 318 to process the acquired vitamin D through any of these mechanisms. The identified association 319 between the participants' baseline vitamin D level and their race and education level is in 320 agreement with previous findings that indicate a higher risk of vitamin D deficiency in non-321 Whites [36,37] and in individuals with a lower education level [36]. Also, lower income, 322 which is strongly associated with lower education level and non-White ethnicity in our data, is 323 known to be associated with lower vitamin D intake. We found a small and not statistically 324 significant positive correlation between the baseline vitamin D level and the alpha diversity, 325 and a significant association between the baseline vitamin D level and the subjects' 326 microbiome composition. The latter has been associated with the development of allergies, 327 asthma or other respiratory diseases [38]. Because an adequate vitamin D level has been 328 iteratively found to be protective against airway inflammation processes [39], immune-329 mediated disorders [4,40], and inflammation [5], our finding may help fill in some of the 330 mechanistic gaps in the microbiome-vitamin D-asthma axis.

331

VDAART was originally designed to evaluate the impact of prenatal maternal vitamin D
supplementation on asthma and respiratory diseases in children [29,34,35] but it also provides
an opportunity to evaluate other effects of the treatment assignment. We found that while most

335 mothers' vitamin D level increased over the trial period, especially so for those on the 336 treatment group, their microbiome composition seems to not be affected by the treatment 337 assignment. This suggests that vitamin D supplementation during pregnancy might be 338 beneficial for the mothers in protecting them against vitamin D deficiency-related disorders 339 and, potentially, for their offspring [21,22,41] without impacting the mothers' risk with 340 respect to microbiome shifts during the pregnancy period. However, depending on the 341 chronicity of vitamin D deficiency prior to pregnancy, there may be physiologic adaptations to 342 deficiency that may need longer periods of supplementation prior to pregnancy to effect 343 change in the mothers' vitamin D levels. Consequently, and based on our finding of an 344 association between baseline vitamin D level and microbiome composition, in order for 345 changes in the microbiome to be consistently detected across different microbiome-related 346 downstream analysis, a longer supplementation period in addition to longer periods between 347 measurements might be needed.

348

349 Vitamin D level in people under a supplementation schedule not only depends on their 350 assigned dose, but can be determined by a multitude of factors such as their vitamin D level at 351 baseline, sunlight exposure, diet, the liver's efficiency in converting the absorbed vitamin D 352 into its serum form, adherence to the treatment, the amount of time their vitamin D level has 353 been in a (in)sufficient range, certain health conditions, or genetic predisposition [42]. 354 Therefore, the change in vitamin D level over a certain period allows a more accurate vision of 355 its associations with the microbiome than information on vitamin D intake via supplements or 356 diet. We found enrichment of the genus Desulfovibrio in subjects whose vitamin D level had a 357 low change over the trial period. Desulfovibrio is the most common sulfate-reducing bacteria

358 in the human intestine [43], and is also found in water sediments and environments with 359 extreme temperature or pH [44]. In humans, the presence of *Desulfovibrio* has been 360 associated with an increased incidence of inflammatory bowel diseases [45,46], and may even 361 have a causal role in their pathophysiology [47,48]. Our result might indicate that an adequate 362 vitamin D level can be protective against a higher risk of developing IBD or other related 363 conditions by way of modulating abundance of this gut microbe. This result agrees with 364 previous studies that found negative correlations between Desulfovibrio's abundance and 365 vitamin D dietary [49] and supplements [50] intake. Moreover, the inability to absorb and 366 process vitamin D has been found to cause dysbiosis and the development of sulfate-induced 367 colitis in mice [51]. However, this pathway requires further clarification; for example, our 368 data contradicts the result of an observational study that found a positive correlation between 369 vitamin D dietary intake and *Desulfovibrio* abundance [52]. Interestingly, some evidence of 370 negative correlations between *Desulfovibrio* and respiratory ailments is available [53,54], but 371 we found a positive correlation with the mothers' history of asthma. On the other hand, we 372 found that no children in the VDAART trial with asthma had a presence of Desulfovibrio in 373 their gut microbiome, but the genus was found in only a tiny proportion of the subjects. Thus, 374 more studies in this direction are necessary to establish a conclusive association. Our data 375 revealed an increased prevalence of *Desulfovibrio* in participants of more disadvantaged 376 backgrounds (lower income and education level), as well as an important difference between 377 the race groups. To our knowledge, this link has not been explored in depth before, and studies 378 that aim to address this gap would help establish an association.

379

380 Some limitations of this study are the relatively small sample size, short trial duration, lack of 381 metagenomic sequencing and the lack of stool microbiome data from the 1<sup>st</sup> trimester of 382 pregnancy. The small sample size could potentially decrease the generalizability of our results, 383 although we do have a diverse cohort from geographically distant study sites. The duration of 384 the study, both in terms of the supplementation duration and the time between baseline 385 measurements and follow up, might hinder from detecting changes in the microbiome more 386 robustly. 16s rRNA sequencing offers many advantages over shotgun metagenomic 387 sequencing such as the lower cost, sensitivity to contamination and bioinformatic 388 requirements, with the drawback that is limited to the 16s region of the rRNA gene only, 389 leading to a loss in resolution in terms of taxonomic detection capabilities. While 16s rRNA 390 sequencing has been the most prevalent genetic marker for decades, full gene sequencing data 391 would allow a more in-depth analysis of the role that vitamin D plays in the microbiome 392 during pregnancy. Finally, the availability of gut microbiome data at enrollment would 393 provide a more accurate comparison of the vitamin D supplementation effects on the 394 microbiome by establishing a baseline microbiome status for every participant. 395

In summary, here we have shown evidence that suggests that the vitamin D level in serum is linked to the gut microbiome composition in pregnant women, but not to its richness. Also, that the gut microbiome seems to be robust to vitamin D supplementation during pregnancy, but that an increase in vitamin D level between the first and third trimesters of pregnancy, in addition to all its other well-known health benefits, could protect against the growth of sulfate-reducing bacteria, such as *Desulfovibrio*, which is associated to several respiratory and bowel inflammation-related ailments.

403

### 404 Authors' contributions

- 405 STW, KLS, and YYL designed research; AA, KLS, and YYL conducted research; DRG, and
- 406 AAL, provided essential databases, AA performed statistical analysis; AA wrote paper with
- 407 input from KLS and YYL; AA, KLS, and YYL had primary responsibility for final
- 408 content; all authors have read and approved the final manuscript.
- 409
- 410 Data sharing
- 411 Microbiome sequencing data from VDAART are part of the ECHO consortium
- 412 and ECHO consortium members can obtain the data directly from the ECHO DCC or for those
- 413 not part of ECHO directly from the authors. All other relevant data are available from the
- 414 authors upon reasonable requests.
- 415
- 416 Code sharing
- 417 Code used to generate the results is available from the authors upon requests.

## References

- [1] M. F. Holick, Vitamin D and Bone Health, The Journal of Nutrition 126, 1159S (1996).
- [2] E. Laird, M. Ward, E. McSorley, J. J. Strain, and J. Wallace, *Vitamin D and Bone Health; Potential Mechanisms*, Nutrients 2, 7 (2010).
- [3] H. F. DeLuca, *Overview of General Physiologic Features and Functions of Vitamin D*, The American Journal of Clinical Nutrition 80, 1689S (2004).
- [4] N. Charoenngam and M. F. Holick, Immunologic Effects of Vitamin D on Human Health and Disease, Nutrients 12, 2097 (2020).
- [5] X. Guillot, L. Semerano, N. Saidenberg-Kermanac'h, G. Falgarone, and M.-C. Boissier, *Vitamin D and Inflammation*, Joint Bone Spine 77, 552 (2010).
- [6] Hana. M. A. Fakhoury, P. R. Kvietys, W. AlKattan, F. A. Anouti, M. A. Elahi, S. N. Karras, and W. B. Grant, *Vitamin D and Intestinal Homeostasis: Barrier, Microbiota, and Immune Modulation*, The Journal of Steroid Biochemistry and Molecular Biology 200, 105663 (2020).
- [7] Y. Wang, J. Zhu, and H. F. DeLuca, *Where Is the Vitamin D Receptor?*, Archives of Biochemistry and Biophysics 523, 123 (2012).
- [8] M. Ardesia, G. Ferlazzo, and W. Fries, *Vitamin D and Inflammatory Bowel Disease*, Biomed Res Int 2015, 470805 (2015).
- [9] R. E. Ley, D. A. Peterson, and J. I. Gordon, *Ecological and Evolutionary Forces Shaping Microbial Diversity in the Human Intestine*, Cell **124**, 837 (2006).
- [10] M. Boirivant, A. Amendola, and A. Butera, *Intestinal Microflora and Immunoregulation*, Mucosal Immunol 1 Suppl 1, S47 (2008).

- [11] C. M. Ferreira, A. T. Vieira, M. A. R. Vinolo, F. A. Oliveira, R. Curi, and F. dos S. Martins, *The Central Role of the Gut Microbiota in Chronic Inflammatory Diseases*, J Immunol Res 2014, 689492 (2014).
- [12] P. J. Kennedy, J. F. Cryan, T. G. Dinan, and G. Clarke, *Irritable Bowel Syndrome: A Microbiome-Gut-Brain Axis Disorder?*, World J Gastroenterol 20, 14105 (2014).
- [13] F. Bellerba et al., *The Association between Vitamin D and Gut Microbiota: A Systematic Review of Human Studies*, Nutrients 13, 3378 (2021).
- [14] N. S. Akimbekov, I. Digel, D. K. Sherelkhan, A. B. Lutfor, and M. S. Razzaque, Vitamin D and the Host-Gut Microbiome: A Brief Overview, Acta Histochem Cytochem 53, 33 (2020).
- [15] M. Waterhouse, Vitamin D and the Gut Microbiome: A Systematic Review of in Vivo Studies, European Journal of Nutrition 16 (2019).
- [16] M. Nuriel-Ohayon, H. Neuman, and O. Koren, *Microbial Changes during Pregnancy*, *Birth, and Infancy*, Front Microbiol 7, 1031 (2016).
- [17] O. Koren et al., Host Remodeling of the Gut Microbiome and Metabolic Changes during Pregnancy, Cell 150, 470 (2012).
- [18] G. M. Fuhler, *The Immune System and Microbiome in Pregnancy*, Best Practice & Research Clinical Gastroenterology 44–45, 101671 (2020).
- [19] J. E. Sordillo et al., Factors Influencing the Infant Gut Microbiome at Age 3-6 Months: Findings from the Ethnically Diverse Vitamin D Antenatal Asthma Reduction Trial (VDAART), Journal of Allergy and Clinical Immunology 139, 482 (2017).

- [20] K. M. Drall et al., Vitamin D Supplementation in Pregnancy and Early Infancy in Relation to Gut Microbiota Composition and C. Difficile Colonization: Implications for Viral Respiratory Infections, Gut Microbes 12, 1799734 (n.d.).
- [21] Z. Kassem et al., Maternal and Cord Blood Vitamin D Level and the Infant Gut Microbiota in a Birth Cohort Study, Maternal Health, Neonatology and Perinatology 6, 5 (2020).
- [22] S. Mandal et al., Fat and Vitamin Intakes during Pregnancy Have Stronger Relations with a Pro-Inflammatory Maternal Microbiota than Does Carbohydrate Intake, Microbiome 4, 55 (2016).
- [23] K. Gorczyca, A. Obuchowska, Ż. Kimber-Trojnar, M. Wierzchowska-Opoka, and B. Leszczyńska-Gorzelak, *Changes in the Gut Microbiome and Pathologies in Pregnancy*, Int J Environ Res Public Health **19**, 9961 (2022).
- [24] I. Kimura et al., Maternal Gut Microbiota in Pregnancy Influences Offspring Metabolic Phenotype in Mice, Science 367, eaaw8429 (2020).
- [25] P. J. Vuillermin, L. Macia, R. Nanan, M. L. Tang, F. Collier, and S. Brix, *The Maternal Microbiome during Pregnancy and Allergic Disease in the Offspring*, Semin Immunopathol **39**, 669 (2017).
- [26] J. A. Ishimwe, Maternal Microbiome in Preeclampsia Pathophysiology and Implications on Offspring Health, Physiol Rep 9, (2021).
- [27] K. A. Lee-Sarwar et al., *The Maternal Prenatal and Offspring Early-Life Gut Microbiome* of Childhood Asthma Phenotypes, Allergy **78**, 418 (2023).
- [28] A. L. Dunlop, J. G. Mulle, E. P. Ferranti, S. Edwards, A. B. Dunn, and E. J. Corwin, *The Maternal Microbiome and Pregnancy Outcomes That Impact Infant Health: A Review*, Adv Neonatal Care 15, 377 (2015).

- [29] A. A. Litonjua et al., The Vitamin D Antenatal Asthma Reduction Trial (VDAART): Rationale, Design, and Methods of a Randomized, Controlled Trial of Vitamin D Supplementation in Pregnancy for the Primary Prevention of Asthma and Allergies in Children, Contemp Clin Trials 38, 37 (2014).
- [30] P. J. McMurdie and S. Holmes, *Phyloseq: An R Package for Reproducible Interactive Analysis and Graphics of Microbiome Census Data*, PLOS ONE **8**, e61217 (2013).
- [31] Oksanen J, Blanchet FG, Friendly M, Kindt R, Legendre P, McGlinn D, et al., Vegan: Community Ecology Package, Package Version 2.6-4, (unpublished).
- [32] H. Lin and S. D. Peddada, Analysis of Compositions of Microbiomes with Bias Correction, Nat Commun 11, 1 (2020).
- [33] H. Mallick et al., *Multivariable Association Discovery in Population-Scale Meta-Omics Studies*, PLOS Computational Biology 17, e1009442 (2021).
- [34] A. A. Litonjua et al., Effect of Prenatal Supplementation With Vitamin D on Asthma or Recurrent Wheezing in Offspring by Age 3 Years: The VDAART Randomized Clinical Trial, JAMA 315, 362 (2016).
- [35] A. A. Litonjua et al., Six-Year Follow-up of a Trial of Antenatal Vitamin D for Asthma Reduction, New England Journal of Medicine 382, 525 (2020).
- [36] A. Zadshir, N. Tareen, D. Pan, K. Norris, and D. Martins, *The Prevalence of Hypovitaminosis D Among US Adults: Data from the NHANES III*, Ethnicity & Disease 15, 97 (2005).
- [37] A. A. Ginde, M. C. Liu, and C. A. Camargo, Demographic Differences and Trends of Vitamin D Insufficiency in the US Population, 1988–2004, Arch Intern Med 169, 626 (2009).

- [38] D. G. Peroni, G. Nuzzi, I. Trambusti, M. E. Di Cicco, and P. Comberiati, *Microbiome Composition and Its Impact on the Development of Allergic Diseases*, Front Immunol 11, 700 (2020).
- [39] N. S. Ali and K. Nanji, A Review on the Role of Vitamin D in Asthma, Cureus 9, e1288 (n.d.).
- [40] F. Baeke, T. Takiishi, H. Korf, C. Gysemans, and C. Mathieu, Vitamin D: Modulator of the Immune System, Curr Opin Pharmacol 10, 482 (2010).
- [41] C. R. Gale, S. M. Robinson, N. C. Harvey, M. K. Javaid, B. Jiang, C. N. Martyn, K. M. Godfrey, and C. Cooper, *Maternal Vitamin D Status during Pregnancy and Child Outcomes*, Eur J Clin Nutr **62**, 68 (2008).
- [42] W. Tsiaras and M. Weinstock, *Factors Influencing Vitamin D Status*, Acta Derm Venerol **91**, 115 (2011).
- [43] J. Loubinoux, F. M. A. Valente, I. A. C. Pereira, A. Costa, P. A. D. Grimont, and A. E. 2002 Le Faou, *Reclassification of the Only Species of the Genus Desulfomonas, Desulfomonas Pigra, as Desulfovibrio Piger Comb. Nov.*, International Journal of Systematic and Evolutionary Microbiology 52, 1305 (n.d.).
- [44] G. Muyzer and A. J. M. Stams, *The Ecology and Biotechnology of Sulphate-Reducing Bacteria*, Nat Rev Microbiol 6, 6 (2008).
- [45] I. Kushkevych, D. Dordević, P. Kollar, M. Vítězová, and L. Drago, Hydrogen Sulfide as a Toxic Product in the Small–Large Intestine Axis and Its Role in IBD Development, J Clin Med 8, 1054 (2019).

- [46] J. Loubinoux, J.-P. Bronowicki, I. A. C. Pereira, J.-L. Mougenel, and A. E. Faou, Sulfate-Reducing Bacteria in Human Feces and Their Association with Inflammatory Bowel Diseases, FEMS Microbiol Ecol 40, 107 (2002).
- [47] I. Kushkevych, J. Kos, P. Kollar, K. Kralova, and J. Jampilek, Activity of Ring-Substituted 8-Hydroxyquinoline-2-Carboxanilides against Intestinal Sulfate-Reducing Bacteria Desulfovibrio Piger, Med Chem Res 27, 278 (2018).
- [48] I. Kushkevych, O. Leščanová, D. Dordević, S. Jančíková, J. Hošek, M. Vítězová, L. Buňková, and L. Drago, *The Sulfate-Reducing Microbial Communities and Meta-Analysis of Their Occurrence during Diseases of Small–Large Intestine Axis*, J Clin Med 8, 1656 (2019).
- [49] Y. J. Weng et al., Correlation of Diet, Microbiota and Metabolite Networks in Inflammatory Bowel Disease, Journal of Digestive Diseases 20, 447 (2019).
- [50] V. T. Pham, S. Fehlbaum, N. Seifert, N. Richard, M. J. Bruins, W. Sybesma, A. Rehman, and R. E. Steinert, *Effects of Colon-Targeted Vitamins on the Composition and Metabolic Activity of the Human Gut Microbiome- a Pilot Study*, Gut Microbes 13, 1 (2021).
- [51] J. H. Ooi, Y. Li, C. J. Rogers, and M. T. Cantorna, Vitamin D Regulates the Gut Microbiome and Protects Mice from Dextran Sodium Sulfate–Induced Colitis, The Journal of Nutrition 143, 1679 (2013).
- [52] M. Garg, P. Hendy, J. N. Ding, S. Shaw, G. Hold, and A. Hart, *The Effect of Vitamin D on Intestinal Inflammation and Faecal Microbiota in Patients with Ulcerative Colitis*, Journal of Crohn's and Colitis **12**, 963 (2018).
- [53] K. L. Bowerman et al., Disease-Associated Gut Microbiome and Metabolome Changes in Patients with Chronic Obstructive Pulmonary Disease, Nat Commun 11, 1 (2020).

[54] K.-H. Sohn, M. Baek, S.-M. Choi, B. Bae, R. Y. Kim, Y.-C. Kim, H.-Y. Kim, H. Yi, and and H.-R. Kang, *Alteration of Lung and Gut Microbiota in IL-13-Transgenic Mice Simulating Chronic Asthma*, **30**, 1819 (2020).

## **Tables**

			Baseline vitamin D level			
		Size (%)	Mean	SD	n valua	
		114 (100%)	21.08	9.07	<i>p</i> value	
	Black	53 (46.5)	16.21	6.49		
Race	Other	34 (29.8)	23.03	9.47	$3.6 \times 10^{-9}$	
	White	27 (23.7)	28.18	7.33		
	50k or more	35 (30.7)	26.01	8.11		
Household	Less than 50k	50 (43.9)	19.45	9.73	$2.8 \times 10^{-4}$	
Income	NA	29 (25.4)	17.93	6.41		
	College or	94 (82.5)	22.08	9.21		
Education	more Highschool, technical school or less	20 (17.5)	16.36	6.77	0.010	
	Boston	51 (44.7)	21.01	8.57		
Site name	San Diego	15 (13.2)	28.74	8.61	0.001	
	Saint Louis	48 (42.1)	18.76	8.56		
Maternal	No	75 (65.8)	21.24	9.25	0.706	
asth ma	Yes	39 (34.2)	20.77	8.82	0.796	
Maternal hay	No	49 (43.0)	21.04	10.01	0.071	
fever	Yes	65 (57.0)	21.11	8.37	0.971	
Maternal age		27.56 (5.85)	27.56	5.85	0.326	
Difference vitamin D level		11.18 (11.30)	11.18	11.3	0.796	
Treatmont	High dose	59 (51.8)	21.64	9.61	0.020	
i reatment	Low dose	55 (48.2)	20.48	8.49	0.929	

Table 1: Summary of the participants' characteristics with respect to their measurement

of Serum 25-hydroxyvitamin D 25(OH)D level at enrollment (baseline vitamin D level).

				Treatment assignment			
		Overall	Treatment	Placebo	n voluo		
		114	59	55	<i>p</i> value		
	Black	53 (46.5)	26 (44.1)	27 (49.1)			
Race	Other	34 (29.8)	20 (33.9)	14 (25.5)	0.614		
	White	27 (23.7)	13 (22.0)	14 (25.5)			
	50k or more	35 (30.7)	19 ( 32.2)	16 (29.1)			
Household income (%)	Less than 50k	50 (43.9)	25 ( 42.4)	25 (45.5)	0.927		
	NA	29 (25.4)	15 ( 25.4)	14 (25.5)			
	College or more	94 (82.5)	48 ( 81.4)	46 ( 83.6)			
Education (%)	Highschool, technical	20 (17.5)	11 ( 18.6)	9 (16.4)	0.941		
	school or less						
Baseline vitamin D level (mean (SD))		21.08 (9.07)	21.64 (9.61)	20.48 (8.49)	0.496		
	Boston	51 (44.7)	29 ( 49.2)	22 ( 40.0)			
Site name (%)	San Diego	15 (13.2)	8 (13.6)	7 (12.7)	0.543		
	Saint Louis	48 (42.1)	22 ( 37.3)	26 (47.3)			
	No	75 (65.8)	39 ( 66.1)	36 ( 65.5)	1.000		
Maternal astnma (%)	Yes	39 (34.2)	20 ( 33.9)	19 ( 34.5)			
	No	49 (43.0)	26 ( 44.1)	23 ( 41.8)	0.050		
Maternal hay fever (%)	Yes	65 (57.0)	33 ( 55.9)	32 ( 58.2)	0.958		
Maternal age (mean (SD))		27.56 (5.85)	27.47 (5.55)	27.65 (6.19)	0.871		

Table 2: Summary of the participants' characteristics with respect to the treatment

group they were assigned to.

## **Figures**



**Figure 1: Vitamin D status was measured in three different ways**: baseline vitamin D level (serum 25-hydroxyvitamin D 25(OH)D [ng/mL] measured in a blood sample at enrollment), treatment assignment (treatment or placebo vitamin D supplementation), and vitamin D level change over the trial period (high change or an increase of at least 10 ng/mL between the enrollment and third trimester, and low change or a difference of less than 10 ng/mL). **a.-c.** The colors of the markers in the three panels represent the treatment assignment of every participant. **a**. Distribution of baseline vitamin D level of all the participants. The black marker represents the mean baseline vitamin D level in all participants (21.01 ng/mL). The treatment assignment is not associated to the baseline vitamin D level. **b.** Baseline vitamin D level vs final vitamin D level. The orange line and band trace a difference of 0±3 ng/mL between the

baseline and the final measurements. The gray line traces a difference of 10 ng/mL between baseline and final measurements. Most of the participants had an increase in their vitamin D level over the trial period. **c**. Distribution of the Vitamin D level difference over the trial period. The black marker represents the mean vitamin D difference in all participants (11.27 ng/mL); the black horizontal line represents the cut-off of 10ng/mL that separates the high and low change groups. **d**. Distribution of the participants' baseline vitamin D level stratified by the different characteristics. The baseline vitamin D value is significantly associated with the participants' education, income, and race.

medRxiv preprint doi: https://doi.org/10.1101/2023.04.04.23288136; this version posted April 5, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



Figure 2: The baseline vitamin D is associated with the microbiome composition but not with its richness; the microbiome is robust to vitamin D supplementation. a.-b. The red

line traces a linear model fit of the panel's data and the green band represents a 95% confidence interval. **a.** The markers represent every individual's baseline vitamin D level with respect to their alpha diversity. No significant association between the baseline vitamin D level and the alpha diversity indices was found. **b.** Every marker represents the difference between the baseline vitamin D levels of two participants with respect to their corresponding beta diversity measurement. We found a significant association between the baseline vitamin D level and all the beta diversity indices that we analyzed (Bray-Curtis, Jaccard, Unifrac and Weighted-unifrac). Pairs of participants with a larger difference in baseline vitamin D level tend to have more dissimilar microbiome composition than pairs whose baseline vitamin D level is closer to each other. **c.-d.** the black markers represent the mean values, and the black vertical lines represent the standard deviation. **c.** Distribution of the alpha diversity indices among the two treatment groups. We found no association between the microbiome richness

and the subjects' treatment assignment for any of the analyzed alpha diversity indices analyzed (Observed, Shannon and Simpson diversity). **d.** The magenta (green) violins represent the distribution of inter-individual gut microbiome dissimilarity of subjects assigned to the high dose of vitamin D supplementation group (placebo group), labeled as T-T (P-P). The yellow violins represent the distribution of gut microbiome dissimilarity between subjects assigned to the treatment group and those assigned to the placebo group, labeled as T-P. There is no association between the treatment assignment and any of the dissimilarity measures.



**Figure 3: The sulfate-reducing bacteria** *Desulfovibrio* **is overexpressed in subjects with low vitamin D level change. a**. Log fold change of differentially abundant genera. Two genera are enriched in the low change group, and two are depleted (significant ANCOM-BC p-value). When adjusting for multiple comparisons, the association remains significant only for the overexpression of *Desulfovibrio* (significant ANCOM-BC q-value). **b** Vitamin D level change (final-baseline measurement) vs *Desulfovibrio* relative abundance. The vertical solid line represents the 10 ng/mL cut-off that defines the high and low change groups. *Desulfovibrio* is almost exclusively present in participants with low vitamin D level change (left of solid vertical line) and is absent in those that had a vitamin D level difference larger than 15 ng/mL (discontinuous vertical line). The blue line traces a lineal model regression fit with 95% confidence interval (blue transparency). **c.** *Desulfovibrio* relative abundance distribution with

respect to participants' characteristics. A significant association exists between *Desulfovibrio*'s abundance and the subjects' history of asthma, race, income, education, and vitamin D level change. No significant association with the subject's treatment assignment was found. *Desulfovibrio* was not present in White women.